SCHEMBL3663874

SCHEMBL3663874

O=C(O)CN1CCC(C(c2ccccc2)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 3/20 0.53
SOS1 Q07889 1/20 0.51
TACR1 P25103 3/20 0.51
KMT2A Q03164 1/20 0.49
BACE1 P56817 1/20 0.47
MRGPRX1 Q96LB2 1/20 0.46
EPHX1 P07099 1/20 0.46
CACNA2D1 P54289 1/20 0.46
CACNA1B Q00975 1/20 0.46
CACNB1 Q02641 1/20 0.46
CACNA1C Q13936 1/20 0.46
SIGMAR1 Q99720 2/20 0.45
FFAR1 O14842 1/20 0.44
UBE2M P61081 1/20 0.44
DCUN1D1 Q96GG9 1/20 0.44
OPRM1 P35372 2/20 0.44
OPRD1 P41143 2/20 0.44
OPRK1 P41145 2/20 0.44
OPRL1 P41146 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3661573 0.89 BACE1 (0.49) SLC6A9SOS1TACR1BACE1CACNA2D1
SCHEMBL3660510 0.87 SLC6A9 (0.52) SLC6A9SOS1TACR1KMT2AMRGPRX1
SCHEMBL3662230 0.85 BACE1 (0.58) BACE1
SCHEMBL3659873 0.83 SLC6A9 (0.63) SLC6A9SOS1TACR1KMT2AMRGPRX1
SCHEMBL3664104 0.82 CCR5 (0.47) SLC6A9TACR1BACE1CACNA2D1CACNA1B
SCHEMBL3661505 0.80 BACE1 (0.45) SLC6A9TACR1BACE1MRGPRX1CACNA2D1
SCHEMBL29379324 0.79 SLC6A9 (0.69) SLC6A9TACR1KMT2ACACNA2D1CACNA1B
SCHEMBL4139317 0.79 SLC6A9 (0.69) SLC6A9TACR1KMT2ACACNA2D1CACNA1B
SCHEMBL4139313 0.79 SLC6A9 (0.69) SLC6A9TACR1KMT2ACACNA2D1CACNA1B
SCHEMBL4157504 0.79 SLC6A9 (0.69) SLC6A9TACR1KMT2ACACNA2D1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231601-A2 GLYCINE TRANSPORTER-1 INHIBITORS Amgen, Inc (US) 2010-09-29 EP claimed
WO-2009075857-A2 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2009-06-18 WO claimed
US-8258306-B2 Glycine transporter-1 inhibitors AMGEN INC. (US) 2012-09-04 US disclosed
US-20100298341-A1 Glycine Transporter-1 Inhibitors AMGEN INC. 2010-11-25 US disclosed
EP-2231601-A2 GLYCINE TRANSPORTER-1 INHIBITORS Amgen, Inc (US) 2010-09-29 EP disclosed
WO-2009075857-A2 GLYCINE TRANSPORTER-1 INHIBITORS AMGEN INC. (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298341-A1 Glycine Transporter-1 Inhibitors SLC18A2, SLC7A11, SLC6A5 SLC6A9 8/4885SOS1 2021/4885TACR1 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.